Home › Funds › Lynx1 Capital Management LP › CCCC

Lynx1 Capital Management LP position in CCCC

C4 THERAPEUTICS INC · Health Care

Lynx1 Capital Management LP reported holding 7,326,691 shares of CCCC (C4 THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$34.2M, representing 3.95% of its reported portfolio and ranking #5 among its reported holdings. Lynx1 Capital Management LP has disclosed CCCC holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)7.33M sh
Reported value held$34.22M
Portfolio Weight3.95%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lynx1 Capital Management LP's CCCC position evolved

Lynx1 Capital Management LP first disclosed a stake in CCCC in Q3 2023 at 1,019,230 shares (US$1.9M). The position peaked in Q3 2024 at 6,880,527 shares, worth US$39.2M. Across 12 filings, Lynx1 Capital Management LP increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 7,326,691 shares valued at US$34.2M — an increase of 327,789 shares quarter over quarter.. Notable position changes include a 208% increase in Q4 2023 (shares rose 45% over the following quarter), a 89% increase in Q2 2024 (shares rose 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.02M $1.90M New
Q4 2023 3.13M $17.71M Add
Q1 2024 3.63M $29.70M Add
Q2 2024 6.88M $31.79M Add
Q3 2024 6.88M $39.22M Hold
Q4 2024 6.85M $24.67M Hold
Q1 2025 7.10M $11.36M Add
Q2 2025 7.10M $10.15M Hold
Q3 2025 7.10M $15.76M Hold
Q4 2025 7.10M $13.56M Hold
Q1 2026 7.00M $18.41M Reduce
Q2 2026 7.33M $34.22M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CCCC and 13F data

CCCC (C4 THERAPEUTICS INC) is a Health Care company. 51 other funds we track also report a position in CCCC — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$37.4M), Bain Capital Life Sciences Investors, LLC (US$33.5M), Soleus Capital Management, L.P. (US$15.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CCCC

All CCCC fund holders →

FAQ

How long has Lynx1 Capital Management LP held CCCC?

Lynx1 Capital Management LP has disclosed CCCC holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Lynx1 Capital Management LP's current position in CCCC?

As of Q2 2026, Lynx1 Capital Management LP holds 7.33M shares of CCCC (C4 THERAPEUTICS INC), valued at $34.22M, representing 3.95% of its reported portfolio and ranking #5.

Has Lynx1 Capital Management LP been buying or selling CCCC?

In the latest 13F filing (Q2 2026), Lynx1 Capital Management LP increased its position in CCCC. The position peaked in Q3 2024 at 6.88M shares.

Which other funds hold CCCC?

Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Bain Capital Life Sciences Investors, LLC, Soleus Capital Management, L.P., among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.